About this trial
There is debate regarding the efficiency of different dilutions of Botulin toxin type A (BTX-A) injections. Some authors believe that highly diluted BTX-A injections achieve greater neuromuscular blockade resulting in higher spasticity reduction. On the other hand, other researchers suggest that there is no difference in spasticity decrease if either high or low volume toxin is being injected. Studies on this subject lack either the design or the power of study was low. Therefore, there is no clear guideline for an optimal botulinum toxin dilution protocol. In an attempt to have a better understanding, a cross over study was designed. The material will be patients with spastic hemiparesis which will be treated with Botulin toxin at different dilutions. Gait analysis will be used for the evaluation of the Botulin toxin injection on gait improvement. To the best of our knowledge such a trial hasn't been performed yet.
Eligibility criteria
Qualifiers
equinovarus deformity
with an average 3 on Ashworth spasticity scale
able to walk indoors either freely or with a cane.
Disqualifiers
patients suffering from any mental illness that would disturb the gait pattern
patients suffering from musculoskeletal diseases that overtly interfere with the gait
Trial design
Treatments tested in this trial
- Botulinum toxin
- gait analysis